FRI0027 PROGNOSTIC MARKERS FOR PRECLINICAL CARDIOVASCULAR DISEASE IN RHEUMATOID ARTHRITIS AND CORRELATION WITH DISEASE ACTIVITY. (June 2019)

• Record Type: Journal Article
• Authors: Blanken, Annelies; Agca, Rabia; van der Laken, C.J.; Nurmohamed, Michael
• Is Part Of: Annals of the rheumatic diseases. Volume 78(2019)Supplement 2
• Page Start: 674
• Page End: 674
• Publication Date: 2019-06
• Subjects: Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/annrheumdis-2019-eular.4581
• Languages: English
• ISSNs: 0003-4967

Abstract

Abstract : Background: Patients with rheumatoid arthritis (RA) have an elevated cardiovascular (CV) disease risk, explained both by an increased prevalence of traditional CV risk factors and the presence of chronic systemic inflammation that impairs vascular function, leads to thickening of the arterial wall and increased arterial stiffness. Objectives: In this study we investigated the effect of anti-inflammatory treatment on prognostic markers for preclinical cardiovascular disease (arterial wall thickening and arterial stiffness) and the correlation of these markers with RA disease parameters. Methods: Carotid ultrasound (using Artlab echotracking system) was used to determine carotid intima media thickness (IMT) and pulse wave analysis was done with SphygmoCor tonometry to calculate pulse wave velocity (PWV) and augmentation index (AIx). Paired t-test was used to compare PWV, AIx and IMT prior and after 6 months of therapy. Pearson correlation was calculated to investigated the correlation of PWV, AIx and IMT with (natural logarithm of) C-reactive protein (CRP), (natural logarithm of) erythrocyte sedimentation rate (ESR) and disease activity score-28 (DAS28). For correlations, data from both time points were pooled. Results: In total 61 consecutive RA patients (50% early arthritis starting with csDMARD and 50% established RA starting with adalimumab) were asked to undergo arterial analysis just prior to start of therapy and after 6 months. PWV was performed in 45 patients at baseline and 39 at follow-up, IMT in 56 and 45 patients respectively and AIx in 51 and 44 patients respectively. Both signs of arterial stiffness (PWV and AIx) decreased after 6 months of therapy (mean difference 0.7 and 0.8 respectively; table 1 ), although this did not reach statistical significance. IMT remained stable during 6 months of therapy. Conclusion: Arterial stiffness as measured with PWV tended to decrease after 6 months of anti-inflammatory treatment. Arterial stiffness and arterial intima media thickness correlated with clinical disease parameters. Altogether, these changes might suggest that effective antirheumatic therapy has favorable cardiovascular effects. Whether or not this ultimately leads to a significant reduction of "hard" cardiovascular endpoints remains to be established in prospective studies. Disclosure of Interests: Annelies Blanken: None declared, Rabia Agca: None declared, C.J. van der Laken: None declared, Michael Nurmohamed Grant/research support from: AbbVie, Bristol-Myers Squibb, Celgene, Eli Lilly, Janssen, Menarini, MSD, Mundipharma, Pfizer, Roche, Sanofi and UCB, Consultant for: AbbVie, Bristol-Myers Squibb, Celgene, Eli Lilly, Janssen, Menarini, MSD, Mundipharma, Pfizer, Roche, Sanofi and UCB, Speakers bureau: AbbVie, Bristol-Myers Squibb, Celgene, Eli Lilly, Janssen, Menarini, MSD, Mundipharma, Pfizer, Roche, Sanofi and UCB